

(\$ ths)	2011 (updated 2011 (presented on 6m results) on road-show)		Difference, \$ ths	Change, %
Revenue	36,174	26,511	9,663	36%
Bio assets revaluation	31,098	25,470	5,628	22%
COGS (incl. depreciation)	(36,202)	(26,536)	(9,666)	36%
Gross profit	31,069	25,445	5,624	22%
<i>Gross margin, %</i>	<i>46%</i>	<i>49%</i>		
SG&A	(2,139)	(1,892)	(247)	13%
Other operational income/expenses	863	687	176	26%
EBITDA	29,793	24,239	5,553	23%
<i>EBITDA margin, %</i>	<i>44%</i>	<i>47%</i>		
Depreciation	(2,372)	(2,945)	573	-19%
EBIT	27,421	21,294	6,126	29%
<i>EBIT margin, %</i>	<i>41%</i>	<i>41%</i>		
Financial expenses	(2,976)	(1,202)	(1,774)	148%
Income tax	(194)	(138)	(56)	41%
Other non-operational income/expenses	-	-		
Net Income	24,251	19,954	4,296	22%
<i>Net margin, %</i>	<i>36%</i>	<i>38%</i>		